NKGN קפיטליזציה חשבונאית NKGen Biotech

NKGen Biotech, Inc. (NKGN) focuses on developing innovative NK-cell based therapies to combat Alzheimer's disease and is currently in the clinical trial stage. The cultivation process of immune units is automated via robotics, which eliminates human error and facilitates scaling. This chart reflects the current share price, fixed at -0.12, complementing data regarding the company's own cGMP sterile facility in California for the production of biologics.

This metric serves as a filter during asset stress testing, allowing for the exclusion of market volatility to assess the intrinsic value of the business. Book capitalization reflects the difference between all assets and liabilities, while the book equity chart for NKGen Biotech, Inc. (NKGN) demonstrates a financial base constrained by the labor intensity of individual cell cultivation, which hinders the rapid scaling of capital through assembly-line production.